Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oraxol in Cutaneous Angiosarcoma
NCT03544567Phase 2Completed
- Sponsor
- Athenex
- Start
- Dec 2018
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel + encequidar in cutaneous angiosarcoma (cAS), sponsored by Athenex. Primary endpoint: Response rate at 6 months. Started Dec 2018; status: completed.
02
Drugs
paclitaxel + encequidar
03
Conditions
cutaneous angiosarcoma (cAS)
Beyond the preview
Go deeper on NCT03544567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03544567.